| Literature DB >> 32717808 |
Miguel M Santos1, Celso Alves2, Joana Silva2, Catarina Florindo3, Alexandra Costa1, Željko Petrovski1, Isabel M Marrucho3, Rui Pedrosa2, Luís C Branco1.
Abstract
As the development of novel antibiotics has been at a halt for several decades, chemically enhancing existing drugs is a very promising approach to drug development. Herein, we report the preparation of twelve organic salts and ionic liquids (OSILs) from ciprofloxacin and norfloxacin as anions with enhanced antimicrobial activity. Each one of the fluoroquinolones (FQs) was combined with six different organic hydroxide cations in 93-100% yield through a buffer-assisted neutralization methodology. Six of those were isomorphous salts while the remaining six were ionic liquids, with four of them being room temperature ionic liquids. The prepared compounds were not toxic to healthy cell lines and displayed between 47- and 1416-fold more solubility in water at 25 and 37 °C than the original drugs, with the exception of the ones containing the cetylpyridinium cation. In general, the antimicrobial activity against Klebsiella pneumoniae was particularly enhanced for the ciprofloxacin-based OSILs, with up to ca. 20-fold decreases of the inhibitory concentrations in relation to the parent drug, while activity against Staphylococcus aureus and the commensal Bacillus subtilis strain was often reduced. Depending on the cation-drug combination, broad-spectrum or strain-specific antibiotic salts were achieved, potentially leading to the future development of highly bioavailable and safe antimicrobial ionic formulations.Entities:
Keywords: active pharmaceutical ingredients as organic salts and ionic liquids (API–OSILs); antibiotics; ciprofloxacin; fluoroquinolones; ionic liquids; norfloxacin; polymorphism
Year: 2020 PMID: 32717808 PMCID: PMC7464485 DOI: 10.3390/pharmaceutics12080694
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Structures of ciprofloxacin and norfloxacin organic acids used as anions in the previous work and organic halide cations used in this work.
Scheme 1General synthetic methodology for the synthesis of anionic fluoroquinolone (FQ)-based organic salts and ionic liquids (OSILs).
Figure 2FTIR spectra of (A) ciprofloxacin, (B) [C3OMIM][Cip], (C) norfloxacin and (D) [C3OMIM][Nor].
Physical state at room temperature, melting (Tm) and glass transition (Tg) temperatures of ciprofloxacin, norfloxacin and corresponding OSILs.
| Compound | Physical State | Tm/°C | Tg/°C |
|---|---|---|---|
| Ciprofloxacin | White solid | 322.0 [ | - |
| [Ch][Cip] | Pale yellow solid | 111.2 | - |
| [EMIM][Cip] | White solid | 92.9 | 36.7 |
| [C2OHMIM][Cip] | White solid | 111.6 | 49.5 |
| [C2OHDMIM][Cip] | White solid | 197.5 | - |
| [C3OMIM][Cip] | White solid | 112.4 | 46.4 |
| [C16Py][Cip] | Orange paste | - | −10.7 |
| Norfloxacin | White solid | 217.0 [ | |
| [Ch][Nor] | Pale yellow solid | 94.5 | 54.8 |
| [EMIM][Nor] | Yellow solid | 119.9 | 64.6 |
| [C2OHMIM][Nor] | Yellow paste | - | 41.1 |
| [C2OHDMIM][Nor] | White solid | 121.8 | 65.1 |
| [C3OMIM][Nor] | White paste | - | 44.1 |
| [C16Py][Nor] | Yellow paste | - | 5.9 |
Figure 3Water solubility at 25 (green) and 37 °C (yellow) for ciprofloxacin, norfloxacin and corresponding OSILs. Values represent mean ± standard error of the mean (SEM) of at least three independent experiments.
Critical micelle concentrations (CMCs) of [C16Py]Cl, [C16Py][Cip] and [C16Py][Nor] in water at 25 °C.
| Compounds | CMC (mmol/L) |
|---|---|
| [C16Py]Cl | 1.063 (1.067 [ |
| [C16Py][Cip] | 0.0816 |
| [C16Py][Nor] | 0.0539 |
Figure 4Cytotoxicity of free fluoroquinolones, halide salts and prepared FQ–OSILs on 3T3 cells (10 µM) after treatment for 24 h. Values represent mean ± standard error of the mean (SEM) of at least three independent experiments carried out in triplicate. Symbols represent statistically significant differences (ANOVA, Dunnett’s test, p-value < 0.05) when compared to control (*).
Figure 5Dose–response curves of [C16Py]-based salts (0.03–10 µM; 24 h) on 3T3 cells for IC50 determination. Values represent mean ± standard error of the mean (SEM) of at least three independent experiments carried out in triplicate.
Figure 6Growth inhibition (A) Klebsiella pneumonia, (B) Staphylococcus aureus and (C) Bacillus subtilis after exposure to the free fluoroquinolones, starting halide salts and prepared FQ–OSILs at 10 µM for 6 h. Values represent mean ± standard error of the mean (SEM) of at least three independent experiments carried out in triplicate. Symbols represent statistically significant differences (ANOVA, Dunnett’s test, p-value < 0.05) between the FQ–OSILs and control (*), Cip (δ) and Nor (#).
Antimicrobial activity (IC50) values (nM) and relative decrease of inhibitory concentrations (RDIC50) for ciprofloxacin and corresponding OSILs (0.001–10 µM) against the tested microorganisms (in bold are the most relevant IC50 and RDIC50 values). The values in parentheses represent the confidence intervals for 95%.
| Compounds |
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Cip | 196.50 | 29.16 | 3.84 | |||
| (119.6–322.8) | (20.28–41.92) | (0.25–58.16) | ||||
| [Ch][Cip] |
|
| 181.4 | 0.2 |
|
|
| (38.44–67.99) | (122.9–267.9) | (18.86–22.49) | ||||
| [EMIM][Cip] |
|
|
|
|
|
|
| (56.61–74.17) | (15.79–37.19) | (12.10–21.60) | ||||
| [C2OHMIM][Cip] |
|
| 61.95 | 0.5 |
|
|
| (32.63–40.66) | (34.10–112.50) | (14.47–17.16) | ||||
| [C2OHDMIM][Cip] |
|
|
|
|
|
|
| (44.04–59.04) | (18.03–24.93) | (8.31–18.35) | ||||
| [C3OMIM][Cip] |
|
| 82.05 | 0.4 |
|
|
| (39.64–57.19) | (48.99–137.40) | (17.12–27.40) | ||||
| [C16Py][Cip] |
|
| 1430 | 0.0 |
|
|
| (4.21–23.17) | (1140.0–1793.0) | (5.21–7.06) |
IC50 values (nM) and relative decrease of inhibitory concentrations for 50% activity (RDIC50) for norfloxacin and corresponding OSILs (0.001–10 µM) against the tested microorganisms (in bold are the most relevant IC50 and RDIC50 values). The values in parentheses represent the confidence intervals for 95%.
| Compounds |
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Nor | 255.2 | 123.4 | 117.2 | |||
| (188.6–345.3) | (71.29–213.5) | (97.70–140.60) | ||||
| [Ch][Nor] | 199.4 | 1.3 | 127.1 | 1.0 | 95.49 | 1.2 |
| (179.9–221.0) | (85.17–189.60) | (80.53–113.2) | ||||
| [EMIM][Nor] | 207.5 | 1.2 | 211.2 | 0.6 | 24.48 | 4.8 |
| (185.1–232.5) | (152.6–292.3) | (19.36–30.94) | ||||
| [C2OHMIM][Nor] | 201.0 | 1.3 | 91.70 | 1.3 | 88.61 | 1.3 |
| (182.6–221.1) | (54.08–155.5) | (81.35–96.51) | ||||
| [C2OHDMIM][Nor] |
|
|
|
|
|
|
| (156.1–203.3) | (69.24–91.40) | (126.1–175.7) | ||||
| [C3OMIM][Nor] | 224.5 | 1.1 | 106.7 | 1.1 | 68.12 | 1.7 |
| (189.5–266.0) | (70.13–162.5) | (56.55–82.06) | ||||
| [C16Py][Nor] | 202.9 | 1.3 |
|
| 87.29 | 1.3 |
| (173.9–236.7) | (2.89–40.67) | (76.04–100.2) |